Unknown

Dataset Information

Open label study of ambrisentan in patients with exercise pulmonary hypertension.


ABSTRACT: A growing body of evidence suggests that exercise pulmonary hypertension (ePH) is an early form of pulmonary arterial hypertension (PAH). Identifying the disease at an early, potentially more responsive phase, and initiating treatment may improve functional status and prevent progression to severe forms of PAH. This was a single-center, open-label six-month treatment trial to evaluate the effect of ambrisentan on pulmonary hemodynamics and exercise capacity in ePH utilizing invasive cardiopulmonary exercise testing (iCPET). After six months of treatment with ambrisentan, patients repeated iCPET; exercise capacity, symptoms, and pulmonary hemodynamics were reassessed. Twenty-two of 30 patients completed the treatment phase and repeat iCPET. After six months of treatment there was a signific

SUBMITTER: Segrera SA 

PROVIDER: S-EPMC5467947 | biostudies-literature | 2017 Apr-Jun

REPOSITORIES: biostudies-literature